Peptidomimetic blockade of MYB in acute myeloid leukemia

Peptidomimetic blockade of MYB in acute myeloid leukemia

MYB activity is a key factor for the maintenance of acute myeloid leukemias but it is also a difficult target. Here, the authors develop a peptidomimetic (MYBMIM) that prevents the interaction of the trans-activation domain of MYB with the KIX domain of CBP/P300 and inhibits leukaemia growth.

Bibliographic Details
Main Authors: Kavitha Ramaswamy, Lauren Forbes, Gerard Minuesa, Tatyana Gindin, Fiona Brown, Michael G. Kharas, Andrei V. Krivtsov, Scott A. Armstrong, Eric Still, Elisa de Stanchina, Birgit Knoechel, Richard Koche, Alex Kentsis
Format: Article
Language:English
Published: Nature Publishing Group 2018-01-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-017-02618-6
id doaj-a470abd9ea4643cfb47136bbe875cfb7
record_format Article
spelling doaj-a470abd9ea4643cfb47136bbe875cfb72021-05-11T10:06:53ZengNature Publishing GroupNature Communications2041-17232018-01-019111310.1038/s41467-017-02618-6Peptidomimetic blockade of MYB in acute myeloid leukemiaKavitha Ramaswamy0Lauren Forbes1Gerard Minuesa2Tatyana Gindin3Fiona Brown4Michael G. Kharas5Andrei V. Krivtsov6Scott A. Armstrong7Eric Still8Elisa de Stanchina9Birgit Knoechel10Richard Koche11Alex Kentsis12Molecular Pharmacology Program, Sloan Kettering InstituteMolecular Pharmacology Program, Sloan Kettering InstituteMolecular Pharmacology Program, Sloan Kettering InstituteDepartment of Pathology and Cell Biology, Columbia University Medical Center and New York Presbyterian HospitalMolecular Pharmacology Program, Sloan Kettering InstituteMolecular Pharmacology Program, Sloan Kettering InstituteCenter for Epigenetics Research, Sloan Kettering InstituteDepartment of Pediatrics, Memorial Sloan Kettering Cancer CenterMolecular Pharmacology Program, Sloan Kettering InstituteAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer CenterDepartment of Pediatric Oncology, Dana-Farber Cancer InstituteCenter for Epigenetics Research, Sloan Kettering InstituteMolecular Pharmacology Program, Sloan Kettering InstituteMYB activity is a key factor for the maintenance of acute myeloid leukemias but it is also a difficult target. Here, the authors develop a peptidomimetic (MYBMIM) that prevents the interaction of the trans-activation domain of MYB with the KIX domain of CBP/P300 and inhibits leukaemia growth.https://doi.org/10.1038/s41467-017-02618-6
collection DOAJ
language English
format Article
sources DOAJ
author Kavitha Ramaswamy
Lauren Forbes
Gerard Minuesa
Tatyana Gindin
Fiona Brown
Michael G. Kharas
Andrei V. Krivtsov
Scott A. Armstrong
Eric Still
Elisa de Stanchina
Birgit Knoechel
Richard Koche
Alex Kentsis
spellingShingle Kavitha Ramaswamy
Lauren Forbes
Gerard Minuesa
Tatyana Gindin
Fiona Brown
Michael G. Kharas
Andrei V. Krivtsov
Scott A. Armstrong
Eric Still
Elisa de Stanchina
Birgit Knoechel
Richard Koche
Alex Kentsis
Peptidomimetic blockade of MYB in acute myeloid leukemia
Nature Communications
author_facet Kavitha Ramaswamy
Lauren Forbes
Gerard Minuesa
Tatyana Gindin
Fiona Brown
Michael G. Kharas
Andrei V. Krivtsov
Scott A. Armstrong
Eric Still
Elisa de Stanchina
Birgit Knoechel
Richard Koche
Alex Kentsis
author_sort Kavitha Ramaswamy
title Peptidomimetic blockade of MYB in acute myeloid leukemia
title_short Peptidomimetic blockade of MYB in acute myeloid leukemia
title_full Peptidomimetic blockade of MYB in acute myeloid leukemia
title_fullStr Peptidomimetic blockade of MYB in acute myeloid leukemia
title_full_unstemmed Peptidomimetic blockade of MYB in acute myeloid leukemia
title_sort peptidomimetic blockade of myb in acute myeloid leukemia
publisher Nature Publishing Group
series Nature Communications
issn 2041-1723
publishDate 2018-01-01
description MYB activity is a key factor for the maintenance of acute myeloid leukemias but it is also a difficult target. Here, the authors develop a peptidomimetic (MYBMIM) that prevents the interaction of the trans-activation domain of MYB with the KIX domain of CBP/P300 and inhibits leukaemia growth.
url https://doi.org/10.1038/s41467-017-02618-6
work_keys_str_mv AT kavitharamaswamy peptidomimeticblockadeofmybinacutemyeloidleukemia
AT laurenforbes peptidomimeticblockadeofmybinacutemyeloidleukemia
AT gerardminuesa peptidomimeticblockadeofmybinacutemyeloidleukemia
AT tatyanagindin peptidomimeticblockadeofmybinacutemyeloidleukemia
AT fionabrown peptidomimeticblockadeofmybinacutemyeloidleukemia
AT michaelgkharas peptidomimeticblockadeofmybinacutemyeloidleukemia
AT andreivkrivtsov peptidomimeticblockadeofmybinacutemyeloidleukemia
AT scottaarmstrong peptidomimeticblockadeofmybinacutemyeloidleukemia
AT ericstill peptidomimeticblockadeofmybinacutemyeloidleukemia
AT elisadestanchina peptidomimeticblockadeofmybinacutemyeloidleukemia
AT birgitknoechel peptidomimeticblockadeofmybinacutemyeloidleukemia
AT richardkoche peptidomimeticblockadeofmybinacutemyeloidleukemia
AT alexkentsis peptidomimeticblockadeofmybinacutemyeloidleukemia
_version_ 1721448752860889088

Similar Items